Protocol

Liposomes

Volume 605 of the series Methods in Molecular Biology pp 335-347

Date:

Angiogenic Vessel-Targeting DDS by Liposomalized Oligopeptides

  • Tomohiro AsaiAffiliated withDepartment of Medical Biochemistry and Global COE, School of Pharmaceutical Sciences, University of Shizuoka
  • , Naoto OkuAffiliated withDepartment of Medical Biochemistry and Global COE, School of Pharmaceutical Sciences, University of Shizuoka Email author 

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Liposomal oligopeptides are one of the promising nanocarriers to deliver a drug, DNA or siRNA to target tissues. In this chapter, we describe our methodology to develop liposomal oligopeptides targeting to tumor angiogenic vessels. At first, we introduce our strategies to identify objective peptides. We performed in vivo biopanning using a phage-displayed peptide library and identified Ala-Pro-Arg-Pro-Gly (APRPG) peptide as a ligand for angiogenic vessels. To modify APRPG peptide on the surface of PEGylated liposomes, we synthesized a novel lipid derivative of the peptide, distearoylphosphatidylethanolamine–polyethyleneglycol–APRPG (DSPE–PEG–APRPG). The lipid derivative of APRPG peptide is expected to be readily incorporated into liposomal membrane and enables to present the peptides on the surface of PEGylated liposomes.

We next describe how to evaluate the advantages of liposomal oligopeptides using specific examples; (1) Intratumoral distribution of APRPG–PEG-modified liposomes, (2) Therapeutic efficacy of adriamycin encapsulated in APRPG–PEG-modified liposomes, (3) Preparation of 5′-O-dipalmitoylphosphatidyl 2′-C-cyano-2′-deoxy-1-β-D-arabino-pentofuranosylcytosine (DPP–CNDAC) liposomes modified with APRPG–PEG, and (4) Therapeutic experiment with APRPG–PEG-modified liposomal DPP–CNDAC.

Key words

Oligopeptides Liposomes Polyethyleneglycol Angiogenic vessels APRPG